Licensing · Southeast Asia · Announced 14 Oct 2026
Nxera Pharma → Synmosa Biopharma
Nxera Pharma granted Taiwan's Synmosa Biopharma exclusive rights to license, supply and commercialise the insomnia drug QUVIVIQ (daridorexant) in six Southeast Asian markets plus Australia and New Zealand.
Parties: Nxera Pharma (Japan) → Synmosa Biopharma (Taiwan)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Australia, New Zealand
- Therapeutic area
- CNS / Neurology
- Asset
- QUVIVIQ (daridorexant)
- Announced
- 14 Oct 2026
Our analysis
Why this matters
Nxera Pharma announced on 14 October 2026 an exclusive license, supply and commercialization agreement with Synmosa Biopharma for QUVIVIQ (daridorexant), a dual orexin receptor antagonist for insomnia, in eight markets: Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand. Nxera receives an upfront payment, regulatory milestones, royalties and drug-supply revenue; amounts were not disclosed.
Daridorexant was discovered by Idorsia and is already marketed in Japan and approved in Taiwan, with an application under review in South Korea. Launches in the new markets depend on local approvals.
The full analysis is free to read with a work email on this page.